Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (1775 p.), 2 v.

Edition: Fifth edition.

ISBN: 1-118-41607-4 , 1-118-41612-0 , 1-118-41642-2

Note: Description based upon print version of record. , Cover -- Volume 1 -- Title Page -- Copyright Page -- Contents -- Contributors -- Preface to the First Edition -- Preface to the Fifth Edition -- Tribute -- List of Abbreviations -- Section 1 History and Use of Hematopoietic Cell Transplantation -- Chapter 1 A History of Allogeneic and Autologous HematopoieticCell Transplantation -- How it all began -- History of allogeneic HCT -- 1949-1956: The humoral versus the cellular hypotheses -- 1956-1959: Early efforts in clinical marrow transplantation -- 1955-1967: Progress in animal models of allogeneic HCT -- 1968-1975: The beginning of the modern era of human marrow transplantation -- 1976-1989: Widening application of allogeneic marrow grafting for human patients -- 1989-1999: Progress in the prevention and therapy of CMV disease. New sources of grafts for allogeneic HCT -- 2000-present: Reduced intensity regimens (RIC) allow transplantation of elderly and medically infirm patients. Hematologic grafts induce tolerance for solid organ transplantation -- History of autologous HCT -- 1958-1964: From pre-clinical studies to first clinical transplant efforts -- 1978-1995: The beginning of an era of promising results in autologous HCT -- 1986-2004: Circulating stem cells and cloned hematopoietic growth factors -- 1982-2001: Testing for minimal residual disease and efforts to "purge" grafts for autologous HCT -- 1986-1999: High-dose chemotherapy and transplantation of autologous hematopoietic cells for patients with breast cancer -- 1993-present: Research to improve preparatory regimens and efforts to consolidate post-HCT remissions -- Conclusion -- References -- Chapter 2 Uses and Growth of Hematopoietic Cell Transplantation -- Introduction -- Changing indications for HCT -- Changes in patient selection -- Hematopoietic cell sources -- Autologous transplantation -- Allogeneic transplantation. , Transplantation regimens and supportive care -- Long-term survivors -- Addressing barriers to use of HCT -- Assessing and improving results of HCT -- References -- Section 2 Scientific Basis or Hematopoietic Cell Transplantation -- Section 2a Hematopoiesis and Stem Biology Transplantation -- Chapter 3 Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells -- Introduction -- Generation of HSCs from ESCs -- What have we learned from murine ESCs? -- Derivation of HSCs from hPSCs -- Derivation of hemangioblasts from hESCs -- Derivation of blood-specific lineages from hPSCs -- T cells -- B cells -- NK cells -- Macrophages -- Dendritic cells -- Erythroid cells -- Megakaryocytes/platelets -- Isolation and/or expansion of hPSC-derived HSCs -- Are PSC-derived hematopoietic progenitors capable of engraftment and hematopoietic repopulation? -- Transplantation of HSCs derived from mPSCs -- Transplantation of HSCs derived from human PSCs -- Can we generate immunologically compatible HSCs? -- Creation of a global hPSC bank -- Immune privileged? -- Pluripotent stem cells tailor-made by reprogramming patients' somatic cells (iPS) -- Direct reprogramming of patients' fibroblasts into blood cells -- Conclusion -- References -- Chapter 4 Hematopoietic Stem Cells, Regenerative Medicine, and Leukemogenesis -- Introduction -- Failure of hematopoietic cell transplanters and journals to use appropriate terms to describe the cells that are transplanted -- History of the HSC -- Properties of mouse HSCs and other MPPs -- Genetic pathways for the self-renewal of HSCs -- Migration of HSCs -- Hematopoietic stem cell and progenitor niches -- Ontogeny of HSCs -- The aging of HSCs: clonal selection versus regulated epigenetic change -- Does hematopoiesis only derive from HSCs and do HSCs give rise only to blood?. , The transition from discovery to accepted scientific fact -- Lineage committed hematopoietic progenitor cells -- Considerations for the definition/isolation of hematopoietic progenitors -- Common lymphoid progenitor cells and lymphoid development -- Common myeloid progenitor cells and myeloid development -- Alternative developmental pathways -- Human myeloid progenitors -- Lineage commitment in fetal hematopoiesis -- DC development -- Gene expression profiles of HSCs and their oligolineage progenitors: Gene Expression Commons -- Promiscuous expression of multiple myeloid or lymphoid genes in hematopoietic branchpoints -- Downregulation of genes irrelevant to committed lineages as a critical mechanism of lineage restriction -- Transplantation of HSCs in mouse and human -- Graft engineering -- Immunologic tolerance and HSC transplantation -- Reversing autoimmune diseases with disease-resistant HSCs -- The future of HSC transplantation: replacing myeloablative conditioning with selective depletion of endogenous HSCs and living donors with cell lines as donors -- Stem cell competition and natural chimeras -- Myelogenous leukemias are driven by leukemia stem cells (LSCs), which are at the oligolineage progenitor stages -- Progression to myelogenous leukemias occurs in competitive HSC clones in a stepwise fashion involving both mutations and epigenetic events -- Final leukemic transformation can occur at the level of myeloid progenitors -- Programmed cell death and programmed cell removal are initiated by proto-oncogenic events, and all leukemias (and cancers) overcome both to become LSCs (CSCs) -- Myelodysplastic syndrome is a stage of leukemic progression before programmed cell removal is overcome -- CD47, the "don't eat me" signal that overcomes programmed cell removal, is a target for antileukemia and anticancer therapies -- Conclusions -- References. , Chapter 5 Marrow Microenvironment and Biology of Mobilization of Stem Cells -- Introduction -- Stem cell homeostasis and the components of the bone marrow niche -- Regional differences within the bone marrow -- HSC homing and engraftment -- HSPC mobilization via ablation of niche cell subsets -- Stem cell mobilization -- Clinically available mobilizing agents -- Mobilization of HSPCs with G-CSF -- CXCR4/CXCL12 axis and G-CSF mobilization -- Cellular mediators of G-CSF mobilization -- G-CSF mobilizes HSPCs through a hematopoietic intermediate -- G-CSF suppresses osteoblast lineage cells in the bone marrow -- G-CSF mobilizes HSPCs through the sympathetic nervous system -- HSPC mobilization via pharmacologic disruption of the CXCR4/CXCL12 axis -- Mobilization of HSPCs with the CXCR4 antagonist plerixafor -- Plerixafor and G-CSF mobilize phenotypically different CD34+ cell subsets -- Alternative agents to disrupt the CXCR4/CXCL12 axis -- Mobilization of HSPCs using CXCR4 agonists -- HSPC mobilizing agents that target VLA-4 -- Mobilization of murine HSPCs by small molecule antagonists of VLA-4 -- Other biologic factors involved in mobilization -- Parathyroid hormone (PTH) and mobilization -- Complement and mobilization -- Hypoxia, HIF-1α and mobilization -- Bioactive sphingolipids and mobilization -- Conclusion -- References -- Chapter 6 Expansion of Human Hematopoietic Stem Cells -- Introduction -- Initial attempts at ex vivo stem cell expansion for clinical application using cytokine-based expansion systems -- Pre-clinical approaches for ex vivo HSPC expansion: intrinsic and extrinsic regulators of cell fate -- Notch signaling in hematopoiesis -- Clinical trials using ex vivo expanded/manipulated cord blood HSPC -- Rationale -- Notch-mediated ex vivo expansion systems for clinical application -- Other emerging approaches to ex vivo expansion. , Alternative strategies to overcome the limiting cell dose in CB grafts: ex vivo modulation to enhance HSC homing -- Conclusion -- References -- Chapter 7 Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation -- Introduction -- Brief history of MSCs -- Nomenclature -- Biologic role of MSCs in situ -- Working definition of ex vivo-expanded MSCs for clinical cell therapy -- Cell biology of ex vivo expanded MSCs -- Tissue sources -- Isolation -- Phenotype -- Ex vivo expansion -- Secretome -- Homing and migration -- Lifespan of MSCs -- Immunobiology -- T lymphocytes -- B lymphocytes -- NK cells -- Dendritic cells (DCs) -- General mechanisms of immune modulation -- Immune privilege -- Risks of ex vivo expanded MSCs as cell therapy -- Malignant transformation -- Ectopic tissue formation after systemic infusion -- Opportunistic infections -- Clinical applications -- MSCs to foster engraftment of HSCs following HCT -- Hematopoietic stem cell expansion -- MSCs to treat GVHD -- Future considerations -- References -- Chapter 8 Genetic Manipulation of Hematopoietic Stem Cells -- Introduction and history -- Gene transfer vectors -- Retroviral vectors -- Gammaretroviral vectors -- Lentiviral vectors -- Foamy viral vectors -- Retroviral pseudotypes for HSC gene transfer -- Other vector systems -- Gene editing and targeted gene integration -- Gene transfer to HSCs -- Source of HSCs for gene transfer -- Ex vivo culture conditions -- In vitro assays for HSC gene transfer -- Gene transfer to mouse HSCs -- Immunodeficient xenotransplant mouse models -- Gene transfer to large-animal repopulating cells -- In vivo delivery of transgenes to HSCs -- Expansion of gene-modified cells prior to infusion -- Expansion of gene-marked cells in vivo -- Immune responses to transgenes -- Clinical trials of HSC gene transfer -- Early studies -- Genetic diseases. , Severe combined immunodeficiency syndrome (SCID). , English

Additional Edition: ISBN 1-118-41600-7

Language: English